Manager TitleAgeSince
Director of Finance/CFO 62 01/03/2017
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 50 21/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.61% - - 403M
-1.50%+5.56%-31.01%-13.89% 164B
-0.06%+2.09%-5.92%-6.73% 104B
-1.57%+3.82%-5.93%+47.83% 55.67B
-0.21%-2.74%+50.16%+50.86% 52.92B
-0.47%+10.29%-9.17%-40.43% 42.96B
+1.90%+14.12% - - 32.87B
-0.23%+1.32%-18.94%-45.30% 27.07B
+1.09%+7.57%+62.05%-6.01% 24.79B
-1.13%+6.41%-10.70%-3.51% 21.02B
Average -0.21%+4.65%+3.82%-2.15% 52.53B
Weighted average by Cap. -0.59%+4.47%-6.03%-1.64%

Financials

2017 2018
Net sales 20.15M 17.65M 16.29M 15.21M 28.64M 1.91B 29.29M 196M 75.68M 940M 75.69M 74.03M 3.26B 27.67M 24.23M 22.37M 20.89M 39.32M 2.62B 40.22M 269M 104M 1.29B 104M 102M 4.48B
Net income -21.28M -18.63M -17.2M -16.06M -30.23M -2.01B -30.92M -207M -79.9M -992M -79.9M -78.15M -3.45B -25.12M -22M -20.31M -18.96M -35.7M -2.38B -36.51M -244M -94.34M -1.17B -94.34M -92.27M -4.07B
Net Debt - -
Logo Avedro, Inc.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a ‘single dose pharmaceutical,’ sold primarily in conjunction with the Company’s innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
Employees
-
  1. Stock Market
  2. Stocks
  3. AVDR Stock